Thermo and RITT Program Announce Collaborative R&D Agreement
News Nov 08, 2006
Thermo Electron Corporation has entered into a collaborative research and development agreement with the Research in Immune Tolerance in Transplantation (RITT) program.
The research will be conducted in the RITT Industrial BioDevelopment Laboratory at the Toronto General Hospital.
As part of this collaboration, the RITT Industrial BioDevelopment Laboratory (IBDL) has been equipped with over $1,000,000 (Canadian) of Thermo laboratory equipment, making this one of the IBDL’s biggest investments in a single supplier.
The RITT program is a $10 million initiative that aims to fully understand the biology of transplant rejection in order to develop treatments to prevent it. The program is part of the research arm of the Multi Organ Transplant Program.
As well as equipping the IBDL with biological safety cabinets, incubators, freezers, microplate instrumentation, a KingFisher magnetic particle processor, and a liquid chromatography and mass spectrometry system (LC/MS), Thermo will also support the RITT program’s objectives by funding a post-doctoral research scientist for two years.
The ‘Thermo Electron Corporation Bioanalytical Post-doctoral Fellow’ will work on projects of joint interest to the RITT program and Thermo in the areas of assay development and biomolecule purification using the latest Thermo instrumentation. Additionally, Thermo will provide training workshops in its many areas of expertise.
Dr. Gary Levy, the director of the Multi Organ Transplant Program and the RITT program, and an internationally-renowned expert in organ transplantation stated, "This partnership with a world leader in scientific instrumentation such as Thermo is an exciting step forward."
"This new collaborative environment between industry and academia is key to successfully translating medical research from the bench to the bedside."
"Our collaboration with the RITT program demonstrates our ability to provide customers with total laboratory solutions," said Marc N. Casper, senior vice president of Thermo Electron Corporation.
"In turn, customers can spend less time managing their lab and instead focus on their promise of their research. We look forward to great things to come from RITT."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017